Complete Wegovy vs Mounjaro Dose Comparison Guide
Wegovy vs Mounjaro for Weight Loss: Complete Dose Availability
When comparing Wegovy vs Mounjaro for weight loss, having access to every dose throughout your treatment journey is essential for optimal results. Both prescription-only medicines require careful dose escalation over 16 weeks before reaching maintenance therapy. EverydayMeds stocks the complete range of both treatments, ensuring patients never face supply interruptions during their weight management programme.
Wegovy follows a structured escalation: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), then 2.4mg maintenance from week 17 onwards. Mounjaro follows a similar pattern but with different dose strengths and dual GIP/GLP-1 receptor targeting. Both treatments require clinical assessment to determine suitability, with ongoing prescriber support throughout the dose escalation process.
Wegovy vs Mounjaro Pricing: Every Dose from £79.99
Our pricing structure reflects the complete Wegovy dose range, starting with 0.25mg at £79.99 and progressing to 2.4mg maintenance at £209.99. Bundle options provide convenience for multi-dose orders, including our Intro Trio (0.25mg, 0.5mg, 1mg) at £299.99 and Ultimate Stability Trio (three 2.4mg pens) at £649.99. New customers benefit from code FIRST40 applied at checkout, while returning patients use DOSE25.
When evaluating Wegovy vs Mounjaro for weight loss costs, both treatments represent significant investment in long-term health outcomes. Our bundle pricing eliminates the need for monthly reordering, providing Reliable Supply security. The complete dose escalation typically spans 16 weeks before maintenance, making early treatment planning essential for budget considerations.
Clinical Evidence: Wegovy vs Mounjaro Weight Loss Studies
In clinical trials, Wegovy demonstrated significant weight management support when used alongside diet and exercise modifications. The STEP programme showed patients may achieve substantial weight reduction, with STEP 1 reporting approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021).
Mounjaro's clinical evidence comes from the SURMOUNT trials, showing the dual GIP/GLP-1 mechanism may provide additional weight management benefits. However, direct comparison between Wegovy vs Mounjaro for weight loss requires individual clinical assessment, as trial populations and methodologies differed significantly.
How Wegovy Works for Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural incretin hormones involved in appetite regulation and glucose metabolism. The treatment may help reduce appetite by acting on brain centres that control hunger and satiety signals. Patients often report feeling fuller for longer periods after meals, naturally supporting portion control efforts. The once-weekly injection provides sustained hormone activity throughout the seven-day dosing period. This mechanism works most effectively when combined with reduced-calorie diet and increased physical activity as part of comprehensive weight management.
Complete Ordering Process: Assessment to Delivery
Our streamlined process begins with a 3-minute online clinical assessment covering medical history, current medications, and weight management goals. Qualified prescribers review applications within 3 working days (express 24-hour service available), determining suitability for either Wegovy or Mounjaro based on individual circumstances. Once approved, orders ship via next-day cold-chain delivery maintaining 2-8°C temperature control throughout transit. Our GPhC-registered pharmacy (#9012878) ensures all treatments meet UK regulatory standards. Ongoing prescriber support continues throughout dose escalation and maintenance phases.
Storage and Practical Considerations
Wegovy offers significant storage advantages in the Wegovy vs Mounjaro comparison, remaining stable at room temperature for 6 weeks once removed from refrigeration compared to Mounjaro's 21-day limit. Both treatments require initial refrigerated storage at 2-8°C before first use. The FlexTouch pen design provides easy self-administration with pre-attached needles and dose-locking mechanisms. Dose escalation cannot be skipped or accelerated, requiring adherence to the prescribed 4-week intervals between increases. Travel convenience makes Wegovy particularly suitable for patients with mobile lifestyles or frequent business travel.
Wegovy vs Mounjaro: Dose Escalation Journey Planning
Successful weight management with either treatment requires comprehensive journey planning from initiation through maintenance. EverydayMeds' complete stock holding ensures seamless progression through all dose levels without supply-related treatment interruptions. Our bundle options align with escalation timelines, providing cost-effective ordering while guaranteeing dose availability.
The 16-week escalation period represents a critical foundation phase where tolerance develops and efficacy builds progressively. Maintenance therapy typically continues long-term, making reliable pharmacy partnership essential for sustained success. Both Wegovy and Mounjaro are available from EverydayMeds, with prescriber guidance helping determine the most appropriate choice for individual circumstances.
Complete Treatment Support and Next Steps
Ready to begin your weight management journey with complete dose security? Our clinical team can guide you through the Wegovy vs Mounjaro decision-making process based on your specific health profile and treatment goals. New customers use code FIRST40 at checkout for additional savings, while returning patients apply DOSE25. Start your 3-minute assessment today at https://everydaymeds.co.uk/collections/wegovy for expert clinical review. All treatments are supplied as prescription-only medicines through our GPhC-registered pharmacy (#9012878). Our comprehensive stock holding and next-day delivery service ensure your weight management journey proceeds without interruption from starter dose through maintenance therapy.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
